



ESHG Pharmacogenomics Course

<http://ibk.mf.uni-lj.si/people/dolzan/eshgpgxcourse2025>

Hotel Histria
Portorož – Slovenia
June 04 – 06, 2025



PROGRAMME AT A GLANCE

Day 1: WEDNESDAY June 4th 2025

08.00 – 08.30	Registration
08.30 – 10.15	Session 1: Introduction to Pharmacogenetics
10.15 – 11.00	Coffee break
11.00 – 12.30	Session 2: Pharmacogenomics of Adverse Drug Reactions
12.30 – 14.00	Lunch
14.00 – 15.30	Session 3: Cancer Pharmacogenomics
15.30 – 16.30	Coffee break and poster viewing
16.30 – 18.30	Session 4: Clinical Topics in Pharmacogenomics I
19.00 –	Welcome reception

Day 2: THURSDAY June 5th 2025

08.30 – 10.30	Session 5: Clinical Topics in Pharmacogenomics II
10.30 – 11.00	Coffee break
11.00 – 12.30	Session 6: Clinical Implementation of Pharmacogenetics I
12.30 – 14.00	Lunch
14.00 – 15.30	Workshop 1: Pharmacogenomics Resources
15.30 – 16.30	Coffee break and poster viewing
16.30 – 18.30	Session 7: Novel Biomarkers of Treatment Response
19.00	Conference dinner

Day 3: FRIDAY June 6th 2025

08.30 – 10.00	Workshop 2: Extracting Pharmacogenomic Information from NGS Data
10.00 – 11.00	Coffee break and poster viewing
11.00 – 12.30	Session 8: Clinical Implementation of Pharmacogenetics II
12.30 – 14.00	Lunch
14.00 – 15.15	Session 9: Clinical Implementation of Pharmacogenetics – Discussion Forum
15.15 – 16.00	Coffee break
16.00 – 17.00	Session 10: Closing Lectures
18.00	A guided tour of Piran
19.30	Farewell dinner in Piran

DETAILED PROGRAMME

Day 1: WEDNESDAY June 4th 2025

08.00 – 08.30	Registration
08.30 – 10.15	Session 1: Introduction to Pharmacogenetics (Chair: Vita Dolžan)
08.30 – 08.45	Course Welcome: Vita Dolžan (<i>Slovenia</i>)
08.45 – 09.30	Opening lecture: Pharmacogenomics, validation of the genetic background – Magnus Ingelman-Sundberg (<i>Sweden</i>)
09.30 – 10.15	Pharmacogenomics of drug transporters – Mikko Niemi (<i>Finland</i>)
10.15 – 11.00	Coffee break
11.00 – 12.30	Session 2: Pharmacogenomics of Adverse Drug Reactions (Chair: Erika Cecchin)
11.00 – 11.30	Pharmacogenomics of adverse drug reactions – Julia C. Stingl (<i>Germany</i>)
11.30 – 12.00	Pharmacogenomics of drug-induced liver injury – Ann K. Daly (<i>UK</i>)
12.00 – 12.30	Pharmacogenomics in the prediction of cardiovascular drugs adverse reaction – PgxCARDIODrug – Lana Ganoci (<i>Croatia</i>)
12.30 – 14.00	Lunch
14.00 – 15.30	Session 3: Cancer Pharmacogenomics (Chair: Katja Goričar)
14.00 – 14.30	Pharmacogenomics in cancer treatment – Cristina Rodriguez-Antona (<i>Spain</i>)
14.30 – 15.00	The use of pharmacogenetics to personalize anti-cancer treatment: state of the art and future directions – Erika Cecchin (<i>Italy</i>)
15.00 – 15.15	Pharmacogenomics of thiopurine drugs in pediatric acute lymphoblastic leukemia: towards personalized therapy in Serbia? – Branka Zukić (<i>Serbia</i>)
15.15 – 15.30	Thiopurine pharmacogenomics and TDM in Slovenia – Nataša Karas Kuželički (<i>Slovenia</i>)
15.30 – 16.30	Coffee break and poster viewing
16.30 – 18.30	Session 4: Clinical Topics in Pharmacogenomics I (Chair: Lana Ganoci)
16.30 – 17.00	Pharmacogenetics and psychiatry: impact for suicide prevention – Adrian Llerena (<i>Spain</i>)
17.00 – 17.30	Integrating pharmacogenomic guided prescribing into primary care: the NHS PROGRESS study – John McDermott (<i>UK</i>)
17.30 – 17.50	Pharmacogenetic insights into treatment resistance in psychiatry: a clinical perspective – Milica Pjevac (<i>Slovenia</i>)
17.50 – 18.10	Active pharmacovigilance trial integrating pharmacogenetics, TDM, and drug-drug interaction analyses in oncology – Diletta Pasin (<i>Italy</i>)
18.10 – 18.30	Weight loss maintenance metabolome and microbiome predictors – Tingyu Guo (<i>UK</i>)
19.00 –	Welcome reception

Day 2: THURSDAY June 5th 2025

08.30 – 10.30	Session 5: Clinical Topics in Pharmacogenomics II (Chair: Branka Zukić)
08.30 – 09.00	Pharmacogenomics and polypharmacy in the elderly – Julia C. Stingl (Germany)
09.00 – 09.30	Pharmacogenetics in treatment of cardiovascular diseases – Ron van Schaik (The Netherlands)
09.30 – 10.00	Pharmacogenetics lessons from clinical genetics – Bill Newman (UK)
10.00 – 10.30	Point of care testing in pharmacogenomics – John McDermott (UK)
10.30 – 11.00	Coffee break
11.00 – 12.30	Session 6: Clinical Implementation of Pharmacogenetics I (Chair: Julia C. Stingl)
11.00 – 11.30	Clinical implementation of pharmacogenetics - Finnish experience – Mikko Niemi (Finland)
11.30 – 12.00	Creation of a national pharmacogenomics program – Bill Newman (UK)
12.00 – 12.30	Pharmacogenomics clinical implementation in Spain – Adrian Llerena (Spain)
12.30 – 14.00	Lunch
14.00 – 15.30	Workshop 1: Pharmacogenomics Resources (Chair: Vita Dolžan)
14.00 – 14.30	Bioinformatics tools in pharmacogenomics research – David Vogrinc, Katja Goričar (Slovenia)
14.30 – 15.00	Pharmacogenes in focus: PharmGKB – Vita Dolžan, Katja Goričar (Slovenia)
15.00 – 15.30	Educational resources in pharmacogenetics – Vita Dolžan (Slovenia)
15.30 – 16.30	Coffee break and poster viewing
16.30 – 18.30	Session 7: Novel Biomarkers of Treatment Response (Chair: David Vogrinc)
16.30 – 17.00	Genomic diversity and predictive biomarkers in renal cancer – Cristina Rodriguez-Antona (Spain)
17.00 – 17.30	Pharmacogenomic and epigenomic biomarkers in radiotherapy – Katja Goričar (Slovenia)
17.30 – 17.50	Uncovering treatment-responsive immune pathways in multisystem inflammatory syndrome in children (MIS-C) through single-cell multiomics – Barbara Jenko Bizjan (Slovenia)
17.50 – 18.10	Epigenetic biomarkers of nusinersen treatment in children with SMA – Jernej Kovač (Slovenia)
18.10 – 18.30	miRNA biomarkers in osteoporosis: a pharmacoepigenetic view of teriparatide response – Lucija Ana Vrščaj (Slovenia)
19.00	Conference dinner

Day 3: FRIDAY June 6th 2025

8.30 – 10.00	Workshop 2: Extracting Pharmacogenetic Information from NGS Data (Chair: Branka Zukić)
8.30 – 9.00	PharmGenHUB Project: Population pharmacogenomics in the Western Balkan – Branka Zukić (<i>Serbia</i>)
9.00 – 9.20	PharmCAT: a bioinformatic tool for clinical pharmacogenomics – Nikola Kotur (<i>Serbia</i>)
9.20 – 9.40	From BAM to haplotype: using Stargazer for pharmacogenomic data analysis – Marina Jelovac (<i>Serbia</i>)
9.40 – 10.00	Interpretation of NGS Results: analysis of pharmacogenomic variants – Vladimir Gašić (<i>Serbia</i>)
10.00 – 11.00	Coffee break and poster viewing
11.00 – 12.30	Session 8: Clinical Implementation of Pharmacogenetics II (Chair: Julia C. Stingl)
11.00 – 11.30	Clinical implementation of pharmacogenetics for routine drug prescription: what are the unmet needs – Ron van Schaik (<i>The Netherlands</i>)
11.30 – 12.00	Implementation of pharmacogenetics in the oncological clinical practice: from chemotherapy to oral targeted agents – Erika Cecchin (<i>Italy</i>)
12.00 – 12.30	Implementation of pharmacogenomics testing: lessons learnt from the PREPARE study – Vita Dolžan (<i>Slovenia</i>)
12.30 – 14.00	Lunch
14.00 – 15.15	Session 9: Clinical Implementation of Pharmacogenetics – Discussion Forum (Chair: Vita Dolžan)
15.15 – 16.00	Coffee break
16.00 – 17.00	Session 10: Closing Lectures (Chair: Vita Dolžan)
16.00 – 16.30	Ongoing challenges in implementing pharmacogenomics in the clinic – Ann K. Daly (<i>UK</i>)
16.30 – 17.00	Pharmacogenomics, clinical application today and in the future – Magnus Ingelman-Sundberg (<i>Sweden</i>)
18.00	A guided tour of Piran
19.30	Farewell dinner in Piran